3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Arthritis, Rheumatoid
13
Spondylitis, Ankylosing
5
Colitis, Ulcerative
4
Psoriasis
3
Crohn Disease
3
Uveal Melanoma
1
Thyroid Carcinoma, Anaplastic
1
Spondylarthritis
1
Sarcoidosis
1
Recurrence
1
Plaque Psoriasis
1
Osteoarthritis
1
Nephrotic Syndrome
1
Nephrosis, Lipoid
1
Mucopolysaccharidosis VI
1
Mucopolysaccharidosis II
1
Mucopolysaccharidosis I
1
Mucopolysaccharidoses
1
Melanoma
1
Macular dystrophy, corneal type 1
1
Kidney Diseases
1
Joint Diseases
1
Inflammatory Bowel Diseases
1
Inflammation
1
Hidradenitis Suppurativa
1
Healthy Adult Male
1
Healthy
1
Glomerulosclerosis, Focal Segmental
1
Dupuytren Contracture
1
Autoimmune Diseases
1
Interventions
Paclitaxel
10
trametinib
9
dabrafenib
9
pembrolizumab
5
lenvatinib
5
fosbretabulin
4
Sorafenib
4
Radiotherapy, Intensity-Modulated
4
Doxorubicin
4
Radiotherapy
3
Cisplatin
3
pazopanib
2
efatutazone
2
combretastatin
2
cobimetinib
2
cemiplimab
2
atezolizumab
2
aldesleukin
2
Vemurafenib
2
Trastuzumab
2
Taxes
2
Nivolumab
2
Gefitinib
2
Filgrastim
2
Everolimus
2
Docetaxel
2
Carboplatin
2
Bevacizumab
2
zimberelimab
1
vandetanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Thyroid Carcinoma, Anaplastic
×
Adalimumab
×
Clear all
NCT02516774
2016-01-26
TAM-RT
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1
Withdrawn